Lenvatinib Remedica (Lenvatinib)

Lenvatinib is a targeted oral therapy used in oncology to inhibit tumor growth and angiogenesis in several advanced solid tumours.

• Radioiodine‑refractory differentiated thyroid cancer: prolongs progression‑free survival in patients whose disease no longer responds to radioactive iodine.
• Advanced renal cell carcinoma: improves overall survival and disease control in adults with metastatic disease.
• Unresectable hepatocellular carcinoma: delays tumour progression and extends survival when surgery is not an option.

• Lenvatinib blocks multiple receptor tyrosine kinases—including VEGFR1‑3, FGFR1‑4, PDGFRα, RET and KIT—thereby reducing tumor angiogenesis, cell proliferation, and survival signaling pathways. This multi‑target inhibition disrupts the vascular supply and growth signals that many solid tumours rely on, leading to slowed disease progression.

Lenvatinib is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Hypertension: elevated blood pressure requiring monitoring and possible antihypertensive therapy.
• Diarrhea: may be mild to moderate and manageable with supportive care.
• Fatigue: persistent tiredness affecting daily activities.
• Decreased appetite: reduced food intake leading to weight loss.
• Nausea: occasional upset stomach, often mitigated with anti‑emetics.
• Weight loss: unintended loss of body mass during treatment.

Serious or Rare Side Effects

• Hepatic failure: signs of liver dysfunction such as jaundice or elevated enzymes.
• Severe hemorrhage: bleeding events that may be life‑threatening.
• Arterial thromboembolic events: clot formation in major arteries.
• Gastrointestinal perforation: hole formation in the stomach or intestines.
• Cardiac failure: reduced heart function presenting with shortness of breath.
• Severe infection: opportunistic infections requiring prompt medical attention.

Before initiating Lenvatinib therapy, clinicians should assess baseline health status and monitor for known risks.

• Monitor blood pressure: check regularly because hypertension is frequent and may require treatment.
• Assess liver function: perform baseline and periodic liver enzyme tests to detect hepatic toxicity.
• Evaluate cardiac status: patients with pre‑existing heart disease should be closely observed.
• Review concomitant medications: avoid drugs that strongly affect CYP3A4 metabolism.
• Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Lenvatinib can interact with other medicines that influence its metabolism or increase bleeding risk.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise Lenvatinib plasma levels and toxicity.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower exposure and reduce efficacy.
• Anticoagulants (e.g., warfarin, direct oral anticoagulants): increase risk of severe hemorrhage.

Moderate Interactions (Monitor Closely)

• Antihypertensive agents: blood pressure may fluctuate; dose adjustments may be needed.
• Diuretics: can exacerbate electrolyte disturbances.
• Other tyrosine kinase inhibitors: overlapping toxicities may require careful monitoring.